Oral Compositions Comprising Propolis

Abstract

Oral compositions are provided that comprise a propolis extract; an oral care active compound chosen from: a cationic antibacterial agent, an anti-attachment agent, a biofilm disruption agent, and an anti-inflammatory agent; and a source of fluoride ions. Further, in certain embodiments, the oral composition comprises an anionic polymeric linear polycarboxylate. The oral composition can be in a form of a mouth rinse, a dentifrice, a confectionary, a medicament, or a film. Methods of making and using the oral compositions are also provided.

1 . An oral composition comprising: 
 a propolis extract;    an oral care active compound chosen from: a cationic antibacterial agent, an anti-attachment agent, a biofilm disruption agent or an anti-inflammatory agent; and    a source of fluoride ions.    
   
   
       2 . An oral composition according to  claim 1 , wherein the propolis extract is present in an amount of about 0.0001 to about 3%.  
   
   
       3 . An oral composition according to  claim 1 , further comprising a polyhydric compound and water.  
   
   
       4 . An oral composition according to  claim 1 , wherein the propolis extract comprises one or more active compounds derived from a propolis source in an amount of about 1 to about 5% by weight of the propolis extract.  
   
   
       5 . An oral composition according to  claim 1 , further comprising an anionic polymeric linear polycarboxylate.  
   
   
       6 . An oral composition according to  claim 5 , wherein the anionic polymeric linear polycarboxylate is an anionic polymeric copolymer of methyl vinyl ether and maleic anhydride.  
   
   
       7 . An oral composition according to  claim 1 , wherein the oral care active compound is a cationic antibacterial agent chosen from benzethonium chloride, octenidine, hexetidine, hexamidine, cetyl pyridinium chloride, alexidine, N α -acyl amino acid alkyl ester salts or mixtures thereof.  
   
   
       8 . An oral composition according to  claim 7 , wherein the oral care active compound is chosen from: N α -cocoyl-L-arginine methyl ester, N α -cocoyl-L-arginine ethyl ester, N α -cocoyl-L-arginine propyl ester, N α -stearoyl-L-arginine methyl ester, N α -stearoyl-L-arginine ethyl ester, N α -lauroyl arginine ethyl ester, salts or mixtures thereof.  
   
   
       9 . An oral composition according to  claim 1 , wherein the oral care active compound comprises ethyl lauroyl arginine ester hydrochloride (ELAH) or cetyl pyrindinium chloride (CPC).  
   
   
       10 . An oral composition according to  claim 1 , wherein the oral care active compound is chosen from: enzymes, histatin, furanone, and derivatives or mixtures thereof.  
   
   
       11 . An oral composition according to  claim 1 , wherein the oral care active compound is chosen from: indomethicin, flurbiprofen, ketoprofen, ibuprofen, naproxen, meclofenamic acid, at least one free-B-ring flavonoid, a mixture of at least one free-B-ring flavonoid and at least one flavan, an extract of magnolia, or mixtures thereof.  
   
   
       12 . An oral composition according to  claim 7 , wherein the cationic antibacterial agent is present in an amount of about 0.001 to about 3% by weight.  
   
   
       13 . An oral composition according to  claim 1 , wherein the source of fluoride ions is chosen from sodium fluoride, sodium monofluorophosphate or mixtures thereof.  
   
   
       14 . An oral composition according to  claim 1  in a form of a mouthrinse, dentifrice, confectionary, medicament or film.  
   
   
       15 . An oral composition according to  claim 1 , further comprising one or more carrier ingredients chosen from: surface active agents, viscosity modifiers, thickeners, humectants, diluents, pH modifying agents, emollients, moisturizers, mouth feel agents, sweetening agents, flavoring agents, solvent, water, colorants or preservatives.  
   
   
       16 . An oral composition according to  claim 1 , wherein the oral care active compound is an anti-attachment agent present in an amount of about 0.001 to about 3% by weight.  
   
   
       17 . An oral composition according to  claim 1 , wherein the oral care active compound is an anti-inflammatory agent comprising a non-steroidal anti-inflammatory drug (NSAID).  
   
   
       18 . An oral composition according to  claim 17 , wherein the anti-inflammatory agent is chosen from: indomethicin, flurbiprofen, ketoprofen, ibuprofen, naproxen, meclofenamic acid, at least one free-B-ring flavonoid, a mixture of at least one free-B-ring flavonoid and at least one flavan, an extract of magnolia or mixtures thereof.  
   
   
       19 . An oral composition according to  claim 17 , wherein the anti-inflammatory agent is present in an amount of about 0.001 to about 3% by weight.  
   
   
       20 . An oral composition according to  claim 1 , wherein the oral care active compound comprises a biofilm disruption agent chosen from: an enzyme, histatin, furanone or derivatives or mixtures thereof.  
   
   
       21 . An oral composition according to  claim 20 , wherein the biofilm disruption agent comprises a protease enzyme.  
   
   
       22 . An oral composition according to  claim 21 , wherein the enzyme is papain or ficin.  
   
   
       23 . An oral composition according to  claim 20 , wherein the biofilm disruption agent is present in an amount of about 0.001 to about 3% by weight.  
   
   
       24 . An oral composition according to  claim 1 , further comprising a carrier that comprises a surface active agent chosen from: a non-ionic surfactant, cationic surfactant, betaine surfactant, amphoteric surfactant or mixtures thereof.  
   
   
       25 . A method of preventing bacteria from forming a biofilm on an oral surface comprising the step of applying to said oral surface a composition a composition comprising an oral composition according to  claim 1 .  
   
   
       26 . A method of suppressing an immune system recognition of an antigen in an oral surface of a mammal, comprising administering a composition according to  claim 1  to said oral surface.  
   
   
       27 . A method of reducing an immune system response comprising applying a composition according to  claim 17  to an oral surface.  
   
   
       28 . The method according to  claim 27 , wherein the immune system response is inflammation.  
   
   
       29 . A method of suppressing production of one or more mediators of inflammation on an oral surface, comprising applying an oral composition according to  claim 1  to an oral surface.  
   
   
       30 . A method of maintaining or increasing systemic health of a mammal comprising applying a composition according to  claim 1  to an oral surface of said mammal at least once a day for at least 2 days.  
   
   
       31 . A method of making an oral composition comprising: 
 admixing one or more carrier ingredients to form a homogenous mixture;    adding a fluoride ion source to the mixture;    adding at least one of: a cationic antibacterial agent, an anti-attachment agent, a biofilm disruption agent or an anti-inflammatory agent; and    adding a propolis extract to the homogeneous mixture at temperatures of less than or equal to about 40° C. to form the oral composition.    
   
   
       32 . A method according to  claim 31 , wherein the admixing of one or more carrier ingredients occurs at a temperature greater than or equal to about 40° C.  
   
   
       33 . A method according to  claim 31 , wherein the one or more carrier ingredients are chosen from: surface active agents, viscosity modifiers, thickeners, humectants, diluents, pH modifying agents, emollients, moisturizers, mouth feel agents, sweetening agents, flavoring agents, solvent, water, colorants, and preservatives.